ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2014
Axitinib sensitization of high Single Dose Radiotherapy.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Molecular Mechanism and Research Progress of Sphingolipid Metabolism in Regulating Radiation-induced Apoptosis Using Pan-cancer Analysis.Current cancer drug targets · 2026Review
- Management of critically located brain metastases in patients with precluded survival using customised double-dose prescription-based, adaptive accelerated staged radiosurgery: a long-term retrospective analysis.Radiation oncology (London, England) · 2025Article
- Radiosensitizing the SUMO stress response intensifies single-dose radiotherapy tumor cure.JCI insight · 2025Article
- Use of Carbon Fiber Implants to Improve the Safety and Efficacy of Radiation Therapy for Spine Tumor Patients.Brain sciences · 2025Review
- Acid Sphingomyelinase-Ceramide Induced Vascular Injury Determines Colorectal Cancer Stem Cell Fate.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2022Article
- Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.Molecules (Basel, Switzerland) · 2022Review
- Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.International journal of molecular sciences · 2022Review
- Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment.Biomedicines · 2021Article
- Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.Radiation oncology (London, England) · 2021Article
- The importance of multidisciplinary care for spine metastases: initial tumor management.Neuro-oncology practice · 2020Review
- Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance.Cancers · 2020Review
- Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2020Article
- Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer.Frontiers in cell and developmental biology · 2020Review
- Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury.The Journal of clinical investigation · 2019Article
- Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.The British journal of radiology · 2019Review
- Adaptive hypofractionated gamma knife radiosurgery in the acute management of brainstem metastases.Surgical neurology international · 2019Article
- Pazopanib radio-sensitization of human sarcoma tumors.Oncotarget · 2018Article
- Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2018Article
- The concept of rapid rescue radiosurgery in the acute management of critically located brain metastases: A retrospective short-term outcome analysis.Surgical neurology international · 2018Article
- Enhancing radiosensitivity of melanoma cells through very high dose rate pulses released by a plasma focus device.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeSingle Dose Radiation Therapy (SDRT) provides remarkably high rates of control even for tumors resistant to fractionated radiotherapy. SDRT tumor control depends on acute acid sphingomyelinase-mediated endothelial cell injury and monoclonal antibodies targeting Vascular Endothelial Cell Growth Factor (VEGF) signaling radiosensitized tumor endothelium when delivered immediately prior to irradiation. Here we evaluate the ability of the oral VEGF receptor inhibitor, axitinib, to sensitize tumor endothelium and increase tumor control with SDRT. METHODS AND MATERIALS: Axitinib was added to primary cultured endothelial cells, or administered orally to Sv129/BL6 mice bearing radiosensitive MCA/129 sarcoma or radioresistant B16F1 melanoma flank tumors, followed by SDRT. Endothelial apoptosis was assessed by TUNEL assay or bis-benzamide staining. Mice with irradiated tumors were followed for 90days to evaluate the impact of axitinib on SDRT tumor control.
resultsPre-treatment with axitinib increased acute endothelial cell apoptosis following SDRT in vitro, and in vivo for both MCA/129 and B16F1 tumors. Axitinib correspondingly increased SDRT tumor growth delay and complete response rate (by 40%) for both tumors. Administration precisely 1h before SDRT was critical for radiosensitization.
conclusionsAxitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.